Equitable Trust Co. Has $6.50 Million Holdings in Elanco Animal Health Incorporated $ELAN

Equitable Trust Co. boosted its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 11.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 271,473 shares of the company’s stock after acquiring an additional 28,520 shares during the period. Equitable Trust Co. owned approximately 0.05% of Elanco Animal Health worth $6,496,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ELAN. NewEdge Advisors LLC raised its position in shares of Elanco Animal Health by 133.7% during the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after purchasing an additional 627 shares during the period. Root Financial Partners LLC grew its position in shares of Elanco Animal Health by 50.7% in the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after purchasing an additional 592 shares during the period. Uniplan Investment Counsel Inc. bought a new stake in Elanco Animal Health during the 4th quarter worth approximately $41,000. Torren Management LLC bought a new stake in Elanco Animal Health during the 4th quarter worth approximately $46,000. Finally, Farther Finance Advisors LLC raised its holdings in Elanco Animal Health by 43.6% during the 4th quarter. Farther Finance Advisors LLC now owns 3,089 shares of the company’s stock worth $70,000 after buying an additional 938 shares during the period. 97.48% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have weighed in on ELAN. Weiss Ratings lowered shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, May 11th. JPMorgan Chase & Co. increased their price objective on shares of Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Citigroup raised their price objective on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Piper Sandler reaffirmed an “overweight” rating on shares of Elanco Animal Health in a research report on Monday, June 29th. Finally, Wall Street Zen lowered shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.55.

Insider Activity at Elanco Animal Health

In other news, CEO Jeffrey N. Simmons bought 4,971 shares of the stock in a transaction that occurred on Friday, May 15th. The shares were acquired at an average cost of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the acquisition, the chief executive officer owned 171,971 shares in the company, valued at approximately $3,454,897.39. This represents a 2.98% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Rajeev A. Modi purchased 4,911 shares of the company’s stock in a transaction on Friday, May 15th. The shares were purchased at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the transaction, the insider directly owned 160,812 shares of the company’s stock, valued at approximately $3,272,524.20. This represents a 3.15% increase in their position. The disclosure for this purchase is available in the SEC filing. Corporate insiders own 1.14% of the company’s stock.

Elanco Animal Health Price Performance

NYSE:ELAN opened at $24.63 on Friday. Elanco Animal Health Incorporated has a 52-week low of $13.39 and a 52-week high of $27.72. The company has a market cap of $12.30 billion, a P/E ratio of -49.27, a P/E/G ratio of 1.61 and a beta of 1.68. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.12 and a current ratio of 2.16. The stock’s 50-day simple moving average is $23.39 and its 200 day simple moving average is $23.77.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, beating the consensus estimate of $0.34 by $0.06. The firm had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The business’s quarterly revenue was up 14.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.37 earnings per share. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, sell-side analysts forecast that Elanco Animal Health Incorporated will post 1.11 EPS for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.